The Extraordinary But Uncertain Growth Of The COVID-19 Market
Q1 Sales Of Leading Products
Executive Summary
The value of the COVID-19 market reached more than $8bn in the first quarter, fuelled by mRNA-based vaccines, but the future growth of the sector depends on the rather unpredictable course of the pandemic, and the response of healthcare providers and countries.
You may also be interested in...
Merck’s Oral Antiviral Data In COVID-19 May Change Pandemic Outlook
Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.
Pharma Is Poised For A COVID-19 Recovery; Will Q2 Deliver?
The second quarter could mark a financial turning point for big pharma as demand rebounds from the pandemic, but variability remains across portfolios and therapeutic areas.
Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected
Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.